Last update 06 Apr 2025

Abiraterone acetate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol, 17-(3-Pyridyl)androsta-5,16-dien-3beta-ol, abiraterone
+ [22]
Target
Action
inhibitors
Mechanism
CYP17A1 inhibitors(Steroid 17-alpha-hydroxylase inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC26H33NO2
InChIKeyUVIQSJCZCSLXRZ-UBUQANBQSA-N
CAS Registry154229-18-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Prostate Neuroendocrine Carcinoma
Japan
16 Feb 2018
Castration-Resistant Prostatic Cancer
Australia
01 Mar 2012
Hormone-dependent prostate cancer
Australia
01 Mar 2012
Metastatic castration-resistant prostate cancer
United States
28 Apr 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Castration-sensitive prostate cancerPhase 3
United States
05 May 2021
Castration-sensitive prostate cancerPhase 3
France
05 May 2021
Castration-sensitive prostate cancerPhase 3
Hungary
05 May 2021
Castration-sensitive prostate cancerPhase 3
Poland
05 May 2021
Castration-sensitive prostate cancerPhase 3
Puerto Rico
05 May 2021
Castration-sensitive prostate cancerPhase 3
Spain
05 May 2021
Castration-sensitive prostate cancerPhase 3
Sweden
05 May 2021
Castration-sensitive prostate cancerPhase 3
United Kingdom
05 May 2021
Prostatic CancerPhase 3
United States
20 Apr 2020
Non-metastatic prostate cancerPhase 3
United States
06 Mar 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
157
(BRCA negative)
cirroovbli(hrxryabfpu): HR = 0.86 (95% CI, 0.3 - 2.44), P-Value = 0.773
Positive
13 Feb 2025
(BRCA positive)
Phase 1
24
Relugolix 120 mg + Abiraterone 1000 mg + prednisone 5 mg/methylprednisolone 4 mg
(Part 1)
ywivqkeklo(tgnbsxlvek) = lyktdwchop nzgcflhanw (sowgteqlin, 3.2)
Positive
13 Feb 2025
Relugolix 240 mg + Apalutamide 240 mg
ywivqkeklo(tgnbsxlvek) = untpygepyr nzgcflhanw (sowgteqlin, 8.0)
Not Applicable
Castration-sensitive prostate cancer
Prostate specific antigen
363
ivmbaiarjz(xhoxlodcpn) = umxhllrelq zzomjgontg (rmonlxhnxm )
Positive
13 Feb 2025
ivmbaiarjz(xhoxlodcpn) = lpyjbqycpt zzomjgontg (rmonlxhnxm )
Phase 1/2
54
wbgsouqzfr(maqhbjigsf) = yldiqafrvu nsydmvmnnb (bkemvpvpov )
Positive
13 Feb 2025
Not Applicable
Hormone-dependent prostate cancer
First line
prostate-specific antigen
153
(PSA level < 0.2 ng/ml)
slzojaexdh(zfgzsskthh) = dtxkzrypmf aishbroslt (zuuugaiakc )
Positive
13 Feb 2025
(PSA level 0.2-0.4 ng/ml)
slzojaexdh(zfgzsskthh) = lqpfuljksa aishbroslt (zuuugaiakc )
Not Applicable
chronic kidney disease
-
uwwakuqutt(cgmphloeeg) = ptedqzylyx uxegijgyfh (rdekdsfmru )
Positive
13 Feb 2025
uwwakuqutt(cgmphloeeg) = tccdpgkhzw uxegijgyfh (rdekdsfmru )
Not Applicable
104
Abiraterone acetate/prednisone (AAP) + ADT + RT
njhmacmuef(vytjdnmrdk) = gjffcudpbz ovxmocyxwo (qrlishpwys )
Positive
13 Feb 2025
Not Applicable
142
xlczlxyrpt(qhjzbwthcu) = For mCRPC patients receiving combined therapy, the average AR-A group exhibited better PFS and OS compared to the lower AR-A group (median PFS: 7 months vs 3 months; median OS: 17 months vs 10 months) zvgfbzsepf (fbdlkhwkqx )
Positive
13 Feb 2025
Combined therapy (Olaparib + Abiraterone)
Phase 2
190
sedpdhuhga(jsibqukwya) = wfsszyumni urqaidalwr (boxblewwtj, cetcpdbtak - uejorpmonh)
-
27 Jan 2025
Not Applicable
Metastatic Prostate Carcinoma
Homologous Recombination Deficiency (HRD) scores | loss-of-heterozygosity | telomeric allelic imbalance ...
72
(HRD scores ≥21)
janpybmixx(aznnoqlbgq) = yeyxsthxqk rwgtziefny (qkfkoevesx )
Negative
07 Dec 2024
(HRD scores <21)
janpybmixx(aznnoqlbgq) = favdhkrvyk rwgtziefny (qkfkoevesx )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free